Glenn Miller was Appointed as Chief Technology Officer at MolecularMD

Date of management change: August 08, 2013 

What Happened?

Portland, OR-based MolecularMD has Appointed Glenn Miller as Chief Technology Officer  

 

About the Company

MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.  

 

About the Person

Glenn Miller previously held various technology roles in the Financial Services industry

 

Info Source

News

 
 

Other IT executives who recently changed jobs as well: Fiorilli Leonard, Jones Lewis, Ramazetti David, Woska David, Joerg Chris, Srivastava Richa, Adams James, Ford Misty, Bohman Benjamin, Roberts Ken, Raymond John

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.